Axa S.A. Dyne Therapeutics, Inc. Transaction History

Axa S.A.

$32.2 Billion
Q4 2024

A detailed history of Axa S.A. transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Axa S.A. holds 188,651 shares of DYN stock, worth $2.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

188,651

Previous 188,951 0.16%

Holding current value

$2.6 Million

Previous $6.79 Million 34.52%

% of portfolio

0.01%

Previous 0.02%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$23.56 - $35.55 $7,068 - $10,665	-300 Reduced 0.16%	188,651 $4.44 Million
Q3 2024 Nov 14, 2024	SELL	$31.94 - $47.04 $677,064 - $997,153	-21,198 Reduced 10.09%	188,951 $6.79 Million
Q2 2024 Feb 25, 2025	BUY	$23.65 - $35.63 $508,427 - $765,973	21,498 Added 11.4%	210,149 $7.42 Million
Q2 2024 Aug 14, 2024	SELL	$23.65 - $35.63 $1.62 Million - $2.44 Million	-68,417 Reduced 24.56%	210,149 $7.42 Million
Q1 2024 May 15, 2024	SELL	$13.06 - $29.18 $3.55 Million - $7.93 Million	-271,758 Reduced 49.38%	278,566 $7.91 Million
Q4 2023 Jul 16, 2024	BUY	$6.62 - $13.64 $1.8 Million - $3.71 Million	271,758 Added 97.56%	550,324 $7.32 Million
Q4 2023 Feb 14, 2024	BUY	$6.62 - $13.64 $491,852 - $1.01 Million	74,298 Added 15.61%	550,324 $7.32 Million
Q3 2023 Nov 14, 2023	SELL	$8.6 - $12.18 $14,654 - $20,754	-1,704 Reduced 0.36%	476,026 $4.27 Million
Q2 2023 Aug 14, 2023	BUY	$8.53 - $14.28 $457,353 - $765,650	53,617 Added 12.64%	477,730 $5.37 Million
Q1 2023 May 15, 2023	BUY	$10.88 - $15.0 $601,968 - $829,920	55,328 Added 15.0%	424,113 $4.89 Million
Q4 2022 Feb 14, 2023	BUY	$9.37 - $13.8 $3.46 Million - $5.09 Million	368,785 New	368,785 $4.27 Million

Others Institutions Holding DYN

# of Institutions

213

Shares Held

103M

Call Options Held

135K

Put Options Held

435K

View Full List

About Dyne Therapeutics, Inc.

Ticker DYN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,765,400
Market Cap $714M
Description
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...

More about DYN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account